CONSOLIDATED BALANCE SHEETS (USD $) In Thousands, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012
Current assets:
Cash and cash equivalents	$ 596,347	$ 916,091
Accounts receivable, net	1,643,148	913,835
Inventories, net	1,076,088	531,256
Prepaid expenses and other current assets	257,389	130,279
Assets held for sale	53,457	90,983
Deferred tax assets, net	221,934	195,007
Total current assets	3,848,363	2,777,451
Property, plant and equipment, net	1,221,606	462,724
Intangible assets, net	13,090,339	9,308,669
Goodwill	9,742,003	5,141,366	[1]
Deferred tax assets, net	60,121	76,422
Other long-term assets, net	241,952	183,747
Total assets	28,204,384	17,950,379
Current liabilities:
Accounts payable	412,943	227,384
Accrued liabilities and other current liabilities	1,889,460	1,008,224
Acquisition-related contingent consideration	125,524	102,559
Current portion of long-term debt	360,964	480,182
Deferred tax liabilities, net	64,191	4,403
Total current liabilities	2,853,082	1,822,752
Acquisition-related contingent consideration	255,513	352,523
Long-term debt	17,043,750	10,535,443
Pension and other benefit liabilities	230,978	5,325
Liabilities for uncertain tax positions	159,673	103,658
Deferred tax liabilities, net	2,436,219	1,248,312
Other long-term liabilities	163,979	164,968
Total liabilities	23,143,194	14,232,981
Commitments and contingencies (note 19)
Equity
Common shares, no par value, unlimited shares authorized, 332,757,906 and 303,861,272 issued and outstanding at September 30, 2013 and December 31, 2012, respectively	8,260,010	5,940,652
Additional paid-in capital	251,654	267,118
Accumulated deficit	(3,402,294)	(2,370,976)
Accumulated other comprehensive loss	(160,257)	(119,396)
Total Valeant Pharmaceuticals International, Inc. shareholders’ equity	4,949,113	3,717,398
Noncontrolling interest	112,077	0
Total equity	5,061,190	3,717,398
Total liabilities and equity	$ 28,204,384	$ 17,950,379

[1] Effective in the first quarter of 2013, the Company has two reportable segments: Developed Markets and Emerging Markets. Accordingly, the Company has restated prior period segment information to conform to the current period presentation. For further details, see note 20 titled “SEGMENT INFORMATION”.